UK markets open in 3 hours 58 minutes

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.3700-0.0100 (-0.42%)
At close: 04:00PM EDT
2.3300 -0.04 (-1.69%)
After hours: 04:28PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 234.39M
Enterprise value 125.25M
Trailing P/E 11.63
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)12.37
Price/book (mrq)1.33
Enterprise value/revenue 8.46
Enterprise value/EBITDA -2.42

Trading information

Stock price history

Beta (5Y monthly) 1.01
52-week change 326.06%
S&P500 52-week change 322.64%
52-week high 35.1400
52-week low 31.7800
50-day moving average 33.1123
200-day moving average 33.2255

Share statistics

Avg vol (3-month) 3186.12k
Avg vol (10-day) 3210.17k
Shares outstanding 598.9M
Implied shares outstanding 698.9M
Float 839.64M
% held by insiders 141.87%
% held by institutions 130.23%
Shares short (28 Mar 2024) 4560.59k
Short ratio (28 Mar 2024) 43.18
Short % of float (28 Mar 2024) 41.06%
Short % of shares outstanding (28 Mar 2024) 40.57%
Shares short (prior month 29 Feb 2024) 4628.01k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CHF.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin 0.00%
Operating margin (ttm)-23.92%

Management effectiveness

Return on assets (ttm)-18.18%
Return on equity (ttm)-32.90%

Income statement

Revenue (ttm)14.8M
Revenue per share (ttm)0.17
Quarterly revenue growth (yoy)1,480,000.00%
Gross profit (ttm)N/A
EBITDA -51.95M
Net income avi to common (ttm)-54.23M
Diluted EPS (ttm)-0.7000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)103.05M
Total cash per share (mrq)1.1
Total debt (mrq)3.5M
Total debt/equity (mrq)2.18%
Current ratio (mrq)9.22
Book value per share (mrq)1.71

Cash flow statement

Operating cash flow (ttm)-60.41M
Levered free cash flow (ttm)-42.11M